- The president of the autonomous community Region of Murcia, Ramón Valcárcel, presided over the opening ceremony together with the president and CEO of the company, Víctor Grifols.
- The installations cover a total surface area of 13,000 square meters and are used for producing bags for collecting and storing blood components and for intravenous solutions in semi-rigid plastic containers.
Grifols’ production plant in Murcia is FDA and CE approved for healthcare products and is authorized to manufacture medicines by the Spanish Agency for Medicines and Healthcare Products (AEMPF). The facilities have also been awarded all the corresponding quality, occupational safety and health, and environmental certifications.
Murcia, November 8, 2012.- Grifols inaugurates the extension (phase III of the building complex) to its production facilities in Las Torres de Cotillas, Murcia. The president of the autonomous community Region of Murcia, Ramón Valcárcel presided the opening ceremony. He was accompanied by Víctor Grifols, president and CEO of the company, Pilar Farjas, general secretary of Health, Domingo Coronado, mayor of the local town, and Grifols management team.
Grifols’ installations in the two building complexes located in Murcia occupy a total surface area of 13,000 square meters and are used for producing bags for collecting and storing blood componentsand for intravenous solutions in semi-rigid plastic containers.
This latest extension, designed by Grifols Engineering, (the company’s pharmaceutical engineering company specialized in biotechnology and sterile products) concludes the process to automate the entire parenteral solutions production plant, incorporating the latest technology in this type of production procedure.
The project involved a total investment of 18 million euros. This investment effort will allow the company to extend its production capacity to 40 million units of intravenous solutions in polypropylene bags. In addition, the plant also produces about 7 million units of bags for the collection and storage of blood components. The extension and modernization of the production plant will also benefit the development of new products and enhance expansion into new international markets, responding to the growing demand for such products worldwide.
In this respect, Grifols’ accumulated expertise and the technology it has developed at its Murcia facilities will be exported to Brazil, where together with its Brazilian partner CEI (Comércio Exportação e Importação de Materiais Médicos Ltda,) Grifols has founded the company Gri -Cei for the production of bags for the collection and storage of blood components. One of the major projects for Gri-Cei is to build a new factory. Building work is expected to start shortly, after the land is acquired in the metropolitan area of Curitiba and the building plans are submitted.
New Investments in the Murcia Production Plant
On completion of phase III of the project to extend and automate the facilities, Grifols has initiated phase IV of the project in order to integrate production in a single building complex. Grifols will invest 5 million euros in this new project, included in the company’s investment program, to gradually increase the production capacity at manufacturing facilities in Spain and in the United States.
Such investments reinforce the company’s future commitment to the Murcia region, where it has been present since 1990, with continuous modernization to the facilities in Las Torres de Cotillas. Phase IV of the building complex aims to increase the production of bags for the collection and storage of blood components and to boost the production of pre-diluted injectable drugs. This phase also includes a new office building and extensions to different already existing service buildings, an extension to the automated warehouse reaching a capacity of 8,000 pallets, and converting the Murcia facilities into one of Grifols’ three major logistics platforms in Spain.
Our Prime Concerns: Quality and Safety
Grifols is one of Spain's leading companies in the manufacture and distribution of enteral and parenteral solutions in semi-rigid and glass containers. In addition to manufacturing plants in Murcia, the company has a plant in Parets del Vallès (Barcelona). Both plants manufacture products for intravenous therapy to high quality standards with the corresponding environmental, quality, and occupational safety and health certifications: ISO 90001, ISO 14001, ISO 13485 y OHSAS 18001.
The Murcia facilities are FDA approved for healthcare products. Therefore, products manufactured in Las Torres de Cotillas have the necessary authorization to be marketed in the U.S. Once the integration of the manufacturing processes is completed, Grifols plans to apply for FDA approval for medicines. The plant is also CE approved for healthcare products and is authorized to manufacture medicines by the Spanish Agency for Medicines and Healthcare Products (AEMPF).
About GrifolsGrifols is specialized in the hospital pharmacy sector. In addition to manufacturing biological plasma-derived medicines, Grifols supplies standard parenteral solutions for intravenous therapies and specialized clinical nutrition products, as well as a wide range of sterile items and medical devices through its Hospital division.